|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MON2 |
Gene summary for MON2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MON2 | Gene ID | 23041 |
| Gene name | MON2 homolog, regulator of endosome-to-Golgi trafficking | |
| Gene Alias | MON2 | |
| Cytomap | 12q14.1 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q7Z3U7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23041 | MON2 | CCI_1 | Human | Cervix | CC | 1.35e-04 | 6.40e-01 | 0.528 |
| 23041 | MON2 | CCI_2 | Human | Cervix | CC | 4.64e-13 | 1.41e+00 | 0.5249 |
| 23041 | MON2 | CCI_3 | Human | Cervix | CC | 2.04e-18 | 1.06e+00 | 0.516 |
| 23041 | MON2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 6.95e-22 | -6.66e-01 | 0.0155 |
| 23041 | MON2 | HTA11_2487_2000001011 | Human | Colorectum | SER | 4.31e-03 | -4.38e-01 | -0.1808 |
| 23041 | MON2 | HTA11_2951_2000001011 | Human | Colorectum | AD | 3.31e-05 | -7.95e-01 | 0.0216 |
| 23041 | MON2 | HTA11_347_2000001011 | Human | Colorectum | AD | 4.14e-02 | 3.55e-01 | -0.1954 |
| 23041 | MON2 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.49e-06 | -5.72e-01 | -0.1207 |
| 23041 | MON2 | HTA11_5212_2000001011 | Human | Colorectum | AD | 1.32e-04 | -6.45e-01 | -0.2061 |
| 23041 | MON2 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.05e-12 | -5.98e-01 | 0.096 |
| 23041 | MON2 | HTA11_10711_2000001011 | Human | Colorectum | AD | 4.74e-08 | -5.47e-01 | 0.0338 |
| 23041 | MON2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.56e-15 | -5.87e-01 | 0.0674 |
| 23041 | MON2 | HTA11_11156_2000001011 | Human | Colorectum | AD | 3.59e-03 | -9.05e-01 | 0.0397 |
| 23041 | MON2 | HTA11_6818_2000001021 | Human | Colorectum | AD | 9.04e-08 | -6.08e-01 | 0.0588 |
| 23041 | MON2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 3.50e-19 | -5.57e-01 | 0.294 |
| 23041 | MON2 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 8.27e-08 | -4.37e-01 | 0.3859 |
| 23041 | MON2 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.77e-12 | -7.51e-01 | 0.2585 |
| 23041 | MON2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.39e-37 | -7.72e-01 | 0.3005 |
| 23041 | MON2 | F007 | Human | Colorectum | FAP | 3.87e-02 | -1.97e-01 | 0.1176 |
| 23041 | MON2 | A001-C-207 | Human | Colorectum | FAP | 3.99e-11 | -4.55e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00068927 | Cervix | CC | post-Golgi vesicle-mediated transport | 28/2311 | 104/18723 | 4.31e-05 | 6.61e-04 | 28 |
| GO:00481938 | Cervix | CC | Golgi vesicle transport | 58/2311 | 296/18723 | 2.24e-04 | 2.54e-03 | 58 |
| GO:00164827 | Cervix | CC | cytosolic transport | 33/2311 | 168/18723 | 4.43e-03 | 2.70e-02 | 33 |
| GO:0048193 | Colorectum | AD | Golgi vesicle transport | 109/3918 | 296/18723 | 1.80e-10 | 1.68e-08 | 109 |
| GO:0016482 | Colorectum | AD | cytosolic transport | 68/3918 | 168/18723 | 6.00e-09 | 3.72e-07 | 68 |
| GO:0006892 | Colorectum | AD | post-Golgi vesicle-mediated transport | 45/3918 | 104/18723 | 2.22e-07 | 9.26e-06 | 45 |
| GO:00481931 | Colorectum | SER | Golgi vesicle transport | 79/2897 | 296/18723 | 4.20e-07 | 2.15e-05 | 79 |
| GO:00164821 | Colorectum | SER | cytosolic transport | 46/2897 | 168/18723 | 5.20e-05 | 1.25e-03 | 46 |
| GO:00068921 | Colorectum | SER | post-Golgi vesicle-mediated transport | 31/2897 | 104/18723 | 1.59e-04 | 3.08e-03 | 31 |
| GO:00481932 | Colorectum | MSS | Golgi vesicle transport | 101/3467 | 296/18723 | 9.09e-11 | 9.77e-09 | 101 |
| GO:00164822 | Colorectum | MSS | cytosolic transport | 59/3467 | 168/18723 | 2.29e-07 | 9.79e-06 | 59 |
| GO:00068922 | Colorectum | MSS | post-Golgi vesicle-mediated transport | 40/3467 | 104/18723 | 1.45e-06 | 4.82e-05 | 40 |
| GO:00481934 | Colorectum | FAP | Golgi vesicle transport | 77/2622 | 296/18723 | 2.86e-08 | 2.62e-06 | 77 |
| GO:00068923 | Colorectum | FAP | post-Golgi vesicle-mediated transport | 36/2622 | 104/18723 | 9.23e-08 | 6.22e-06 | 36 |
| GO:00164823 | Colorectum | FAP | cytosolic transport | 47/2622 | 168/18723 | 1.58e-06 | 6.72e-05 | 47 |
| GO:00164824 | Colorectum | CRC | cytosolic transport | 45/2078 | 168/18723 | 1.22e-08 | 2.52e-06 | 45 |
| GO:00068924 | Colorectum | CRC | post-Golgi vesicle-mediated transport | 33/2078 | 104/18723 | 1.22e-08 | 2.52e-06 | 33 |
| GO:00481935 | Colorectum | CRC | Golgi vesicle transport | 59/2078 | 296/18723 | 5.47e-06 | 2.17e-04 | 59 |
| GO:00481939 | Endometrium | AEH | Golgi vesicle transport | 60/2100 | 296/18723 | 3.65e-06 | 9.79e-05 | 60 |
| GO:004819313 | Endometrium | EEC | Golgi vesicle transport | 60/2168 | 296/18723 | 9.91e-06 | 2.17e-04 | 60 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MON2 | SNV | Missense_Mutation | novel | c.2943N>C | p.Gln981His | p.Q981H | Q7Z3U7 | protein_coding | deleterious(0.01) | possibly_damaging(0.596) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MON2 | SNV | Missense_Mutation | novel | c.4924N>C | p.Ile1642Leu | p.I1642L | Q7Z3U7 | protein_coding | deleterious(0.01) | possibly_damaging(0.555) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MON2 | SNV | Missense_Mutation | c.3784N>C | p.Asp1262His | p.D1262H | Q7Z3U7 | protein_coding | tolerated(0.1) | possibly_damaging(0.465) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD | |
| MON2 | SNV | Missense_Mutation | c.4361N>G | p.Pro1454Arg | p.P1454R | Q7Z3U7 | protein_coding | deleterious(0.02) | possibly_damaging(0.88) | TCGA-BH-A202-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR | |
| MON2 | SNV | Missense_Mutation | novel | c.1858N>C | p.Thr620Pro | p.T620P | Q7Z3U7 | protein_coding | tolerated(0.08) | benign(0.098) | TCGA-D8-A1JP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| MON2 | SNV | Missense_Mutation | c.5144N>C | p.Gly1715Ala | p.G1715A | Q7Z3U7 | protein_coding | tolerated_low_confidence(0.05) | probably_damaging(0.994) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MON2 | SNV | Missense_Mutation | rs763331525 | c.4826C>T | p.Ser1609Leu | p.S1609L | Q7Z3U7 | protein_coding | deleterious(0.01) | possibly_damaging(0.578) | TCGA-E2-A14R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | PD |
| MON2 | insertion | Frame_Shift_Ins | novel | c.3667_3668insT | p.Ser1223MetfsTer2 | p.S1223Mfs*2 | Q7Z3U7 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| MON2 | insertion | In_Frame_Ins | novel | c.3668_3669insACTAGGTAC | p.Ser1223delinsArgLeuGlyThr | p.S1223delinsRLGT | Q7Z3U7 | protein_coding | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| MON2 | deletion | Frame_Shift_Del | novel | c.94delN | p.Phe32SerfsTer12 | p.F32Sfs*12 | Q7Z3U7 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |